Chip Baird
Vorstandsvorsitzender bei 2SEVENTY BIO, INC.
Vermögen: 1 Mio $ am 31.05.2024
Profil
William Denise Baird is currently the President, Chief Executive Officer & Director at 2seventy Bio, Inc. and the Chairman at Deep Genomics, Inc. Previously, he served as an Independent Director at Axcella Health, Inc. from 2018 to 2023.
He also held positions as the Chief Financial Officer at Amicus Therapeutics, Inc. from 2012 to 2018 and at PTC Therapeutics, Inc. from 2005 to 2012.
Additionally, he worked as the Chief Financial & Accounting Officer at bluebird bio, Inc. in 2021.
Prior to that, he was an Engagement Manager at The Lek from 1999 to 2002.
Mr. Baird obtained an MBA from The Wharton School of the University of Pennsylvania and completed his undergraduate studies at the Edmund A.
Walsh School of Foreign Service.
Bekannte Unternehmensbeteiligungen
Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
---|---|---|---|---|
2SEVENTY BIO, INC.
0,60% | 01.04.2024 | 308 585 ( 0,60% ) | 1 Mio $ | 31.05.2024 |
AXCELLA HEALTH, INC.
-.--% | 31.10.2023 | 0 ( -.--% ) | - $ | 31.12.2023 |
Aktive Positionen von Chip Baird
Unternehmen | Position | Beginn |
---|---|---|
2SEVENTY BIO, INC. | Vorstandsvorsitzender | 01.04.2024 |
Deep Genomics, Inc.
Deep Genomics, Inc. BiotechnologyHealth Technology Deep Genomics, Inc. provides machine learning, genome biology and precision medicine. It develops an integrated computational system that could learn, predict, and interpret how genetic variation, whether natural or therapeutic, alters crucial cellular processes. The firm offers SPIDEX database, which is a set of genetic variants and their predicted effects on human splicing across the entire genome. Its SPIDEX database covers all synonymous, missense, and nonsense exonic SNVs, as well as intronic SNVs that are up to 300nt from splice junctions. The company was founded by Brendan Frey and Hui Yuan Xiong in 2015 and is headquartered in Toronto, Canada. | Vorsitzender | 15.09.2023 |
Ehemalige bekannte Positionen von Chip Baird
Unternehmen | Position | Ende |
---|---|---|
AXCA HEALPAR | Direktor/Vorstandsmitglied | 01.11.2023 |
BLUEBIRD BIO, INC. | Finanzdirektor/CFO | 04.11.2021 |
AMICUS THERAPEUTICS, INC. | Finanzdirektor/CFO | 19.12.2018 |
PTC THERAPEUTICS, INC. | Finanzdirektor/CFO | 01.04.2012 |
The Lek/Alcar Consulting Group, Inc.
The Lek/Alcar Consulting Group, Inc. Miscellaneous Commercial ServicesCommercial Services The Lek/Alcar Consulting Group, Inc. provides business strategy consulting services. It offers strategy, finance, marketing and sales, operations, and transaction services including business unit strategy, brand management, pricing, alliances and joint ventures, product development, corporate transformation, and operations design. It serves the defense, energy, health, building and construction, aerospace, media, retail, and telecommunications industries. The company was founded by Andrew Kutter in 1983 and is headquartered in Boston, MA. | Corporate Officer/Principal | 01.01.2002 |
Ausbildung von Chip Baird
Edmund A. Walsh School of Foreign Service | Undergraduate Degree |
The Wharton School of the University of Pennsylvania | Masters Business Admin |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Börsennotierte Unternehmen | 5 |
---|---|
PTC THERAPEUTICS, INC. | Health Technology |
AMICUS THERAPEUTICS, INC. | Health Technology |
AXCA HEALPAR | Health Technology |
BLUEBIRD BIO, INC. | Health Technology |
2SEVENTY BIO, INC. | Health Technology |
Private Unternehmen | 3 |
---|---|
The Lek/Alcar Consulting Group, Inc.
The Lek/Alcar Consulting Group, Inc. Miscellaneous Commercial ServicesCommercial Services The Lek/Alcar Consulting Group, Inc. provides business strategy consulting services. It offers strategy, finance, marketing and sales, operations, and transaction services including business unit strategy, brand management, pricing, alliances and joint ventures, product development, corporate transformation, and operations design. It serves the defense, energy, health, building and construction, aerospace, media, retail, and telecommunications industries. The company was founded by Andrew Kutter in 1983 and is headquartered in Boston, MA. | Commercial Services |
Amicus Therapeutics UK Ltd.
Amicus Therapeutics UK Ltd. Miscellaneous Commercial ServicesCommercial Services Part of Amicus Therapeutics, Inc., Amicus Therapeutics UK Ltd. is a company that focuses on delivering high-quality therapies for persons living with rare and orphan diseases. The company is based in Gerrards Cross, UK. The employees of Amicus crafted a belief statement that encompasses their core values and reminds them of the reason they do what they do every day. The statement outlines the fundamental beliefs that are crucial to understanding the passion and commitment behind Amicus. The British company believes in the fight to remain at the forefront of therapies for rare and orphan diseases, supporting the disease communities and their families, and fostering teamwork and respect for each individual's contribution. | Commercial Services |
Deep Genomics, Inc.
Deep Genomics, Inc. BiotechnologyHealth Technology Deep Genomics, Inc. provides machine learning, genome biology and precision medicine. It develops an integrated computational system that could learn, predict, and interpret how genetic variation, whether natural or therapeutic, alters crucial cellular processes. The firm offers SPIDEX database, which is a set of genetic variants and their predicted effects on human splicing across the entire genome. Its SPIDEX database covers all synonymous, missense, and nonsense exonic SNVs, as well as intronic SNVs that are up to 300nt from splice junctions. The company was founded by Brendan Frey and Hui Yuan Xiong in 2015 and is headquartered in Toronto, Canada. | Health Technology |